{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:24:47Z","timestamp":1779110687365,"version":"3.51.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Interv Card Electrophysiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>A novel irrigated radiofrequency balloon (RFB) for pulmonary vein isolation (PVI) integrated into a 3D mapping platform was recently launched.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Patients undergoing a first atrial fibrillation (AF) ablation at two German high-volume EP centers were included into the prospective AURORA registry. All patients underwent clinical follow-up (FU) at 90, 180, and 360\u00a0days following ablation including 48-h Holter ECGs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 99 patients were enrolled (43\/99 (43.4%) women, median age 67\u00a0years (interquartile range [IQR] 59\u201374), 43\/99 (43.4%) persistent AF (Pers-AF), median left ventricular ejection fraction (LVEF) 60% (IQR 62\u201355)). Eighty-eight patients completed the follow-up. Acute PVI was achieved in 383\/383 (100%) PV. Single-shot PVI was achieved in 211\/383 (55.1%) PVs. Primary adverse events occurred in 3% of patients (1 postprocedural pharyngeal bleeding, 1 myocardial infarction, 1 non-cardiovascular death); no pericardial effusion, stroke, or phrenic nerve paralysis was observed. Median ablation and procedure times were 23 (IQR 18\u201332) and 67 (IQR 57\u201385) min, respectively. Median dose area product was 761 (IQR 509\u20131534) mGycm<jats:sup>2<\/jats:sup>. AF-free survival after a median FU of 361 (IQR 261\u2013375) days was 78.4% for paroxysmal AF (PAF) and 75.4% for Pers-AF (<jats:italic>p<\/jats:italic> value\u2009=\u20090.828). Early recurrence of atrial tachyarrhythmia at the 90-day visit was the only independent predictor for AF recurrence at 1\u00a0year upon multiple regression analysis (hazard ratio [HR] 3.198; 95% confidence interval [95% CI] 1.036\u201310.32, <jats:italic>p<\/jats:italic> value\u2009=\u20090.0433).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>RFB-based PVI is acutely successful, appears safe, and has comparable rhythm outcomes to other single-shot AF ablation tools. A recurrence of AF at 90\u00a0days predicts later AF recurrence.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical Abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1007\/s10840-024-01938-0","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T19:28:09Z","timestamp":1731007689000},"page":"835-844","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Radiofrequency balloon ablation: 1-year outcomes of the AURORA study"],"prefix":"10.1007","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1676-4633","authenticated-orcid":false,"given":"Ilaria","family":"My","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Rottner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Tohoku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Lemoine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Schaack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Moser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Urbanek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julius","family":"Obergassel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Djemail","family":"Ismaili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Hirokami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulus","family":"Kirchhof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Plank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Reissmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feifan","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Rillig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Chun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Metzner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Bordignon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"issue":"40","key":"1938_CR1","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1093\/eurheartj\/ehab648","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, et al. Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(40):4194. https:\/\/doi.org\/10.1093\/eurheartj\/ehab648.","journal-title":"Eur Heart J"},{"issue":"14","key":"1938_CR2","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","volume":"383","author":"P Kirchhof","year":"2020","unstructured":"Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020;383(14):1305\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2019422.","journal-title":"N Engl J Med"},{"issue":"13","key":"1938_CR3","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1001\/jama.2019.0693","volume":"321","author":"DL Packer","year":"2019","unstructured":"Packer DL, Mark DB, Robb RA, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA Randomized Clinical Trial. JAMA. 2019;321(13):1261\u201374. https:\/\/doi.org\/10.1001\/jama.2019.0693.","journal-title":"JAMA"},{"key":"1938_CR4","doi-asserted-by":"publisher","unstructured":"Metzner A, Kuck KH, Chun JKR. What we have learned: is pulmonary vein isolation still the cornerstone of atrial fibrillation ablation?. Europace. 2022;24(Suppl 2):ii8-ii13. https:\/\/doi.org\/10.1093\/europace\/euab268","DOI":"10.1093\/europace\/euab268"},{"issue":"7","key":"1938_CR5","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1253\/circj.CJ-23-0220","volume":"87","author":"I My","year":"2023","unstructured":"My I, Bordignon S, Butt M, et al. Novel radiofrequency balloon catheter - impact of ablation parameters on single-shot isolation. Circ J. 2023;87(7):950\u20136. https:\/\/doi.org\/10.1253\/circj.CJ-23-0220.","journal-title":"Circ J"},{"issue":"12","key":"1938_CR6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.119.007541","volume":"12","author":"VY Reddy","year":"2019","unstructured":"Reddy VY, Schilling R, Grimaldi M, et al. pulmonary vein isolation with a novel multielectrode radiofrequency balloon catheter that allows directionally tailored energy delivery: short-term outcomes from a multicenter first-in-human study (RADIANCE). Circ Arrhythm Electrophysiol. 2019;12(12): e007541. https:\/\/doi.org\/10.1161\/CIRCEP.119.007541.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"6","key":"1938_CR7","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1093\/europace\/euaa382","volume":"23","author":"R Schilling","year":"2021","unstructured":"Schilling R, Dhillon GS, Tondo C, et al. Safety, effectiveness, and quality of life following pulmonary vein isolation with a multi-electrode radiofrequency balloon catheter in paroxysmal atrial fibrillation: 1-year outcomes from SHINE. Europace. 2021;23(6):851\u201360. https:\/\/doi.org\/10.1093\/europace\/euaa382.","journal-title":"Europace"},{"issue":"18","key":"1938_CR8","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1056\/NEJMoa2307291","volume":"389","author":"VY Reddy","year":"2023","unstructured":"Reddy VY, Gerstenfeld EP, Natale A, et al. Pulsed field or conventional thermal ablation for paroxysmal atrial fibrillation. N Engl J Med. 2023;389(18):1660\u201371. https:\/\/doi.org\/10.1056\/NEJMoa2307291.","journal-title":"N Engl J Med"},{"issue":"5","key":"1938_CR9","doi-asserted-by":"publisher","first-page":"euad106","DOI":"10.1093\/europace\/euad106","volume":"25","author":"S Bordignon","year":"2023","unstructured":"Bordignon S, My I, Tohoku S, et al. Efficacy and safety in patients treated with a novel radiofrequency balloon: a two centres experience from the AURORA collaboration. Europace. 2023;25(5):euad106. https:\/\/doi.org\/10.1093\/europace\/euad106.","journal-title":"Europace."},{"issue":"6","key":"1938_CR10","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1111\/jce.13927","volume":"30","author":"F Straube","year":"2019","unstructured":"Straube F, Dorwarth U, Pongratz J, et al. The fourth cryoballoon generation with a shorter tip to facilitate real-time pulmonary vein potential recording: feasibility and safety results. J Cardiovasc Electrophysiol. 2019;30(6):918\u201325. https:\/\/doi.org\/10.1111\/jce.13927.","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"7","key":"1938_CR11","doi-asserted-by":"publisher","first-page":"euad185","DOI":"10.1093\/europace\/euad185","volume":"25","author":"B Schmidt","year":"2023","unstructured":"Schmidt B, Bordignon S, Neven K, et al. EUropean real-world outcomes with Pulsed field ablatiOn in patients with symptomatic atRIAl fibrillation: lessons from the multi-centre EU-PORIA registry. Europace. 2023;25(7):euad185. https:\/\/doi.org\/10.1093\/europace\/euad185.","journal-title":"Europace."},{"issue":"3","key":"1938_CR12","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1093\/europace\/euad017","volume":"25","author":"A Del Monte","year":"2023","unstructured":"Del Monte A, Almorad A, Pannone L, et al. Pulmonary vein isolation with the radiofrequency balloon catheter: a single centre prospective study. Europace. 2023;25(3):896\u2013904. https:\/\/doi.org\/10.1093\/europace\/euad017.","journal-title":"Europace"},{"issue":"1","key":"1938_CR13","doi-asserted-by":"publisher","first-page":"17907","DOI":"10.1038\/s41598-021-96820-8","volume":"11","author":"C Wu","year":"2021","unstructured":"Wu C, Li X, Lv Z, et al. Second-generation cryoballoon versus contact force radiofrequency ablation for atrial fibrillation: an updated meta-analysis of evidence from randomized controlled trials. Sci Rep. 2021;11(1):17907. https:\/\/doi.org\/10.1038\/s41598-021-96820-8. (Published 2021 Sep 9).","journal-title":"Sci Rep."},{"issue":"3","key":"1938_CR14","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.jacep.2021.01.011","volume":"7","author":"LA Gottlieb","year":"2021","unstructured":"Gottlieb LA, Dekker LRC, Coronel R. The blinding period following ablation therapy for atrial fibrillation: proarrhythmic and antiarrhythmic pathophysiological mechanisms. JACC Clin Electrophysiol. 2021;7(3):416\u201330. https:\/\/doi.org\/10.1016\/j.jacep.2021.01.011.","journal-title":"JACC Clin Electrophysiol"},{"issue":"4","key":"1938_CR15","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.hrthm.2015.12.034","volume":"13","author":"G Mugnai","year":"2016","unstructured":"Mugnai G, de Asmundis C, H\u00fcn\u00fck B, et al. Second-generation cryoballoon ablation for paroxysmal atrial fibrillation: predictive role of atrial arrhythmias occurring in the blanking period on the incidence of late recurrences. Heart Rhythm. 2016;13(4):845\u201351. https:\/\/doi.org\/10.1016\/j.hrthm.2015.12.034.","journal-title":"Heart Rhythm"},{"issue":"9","key":"1938_CR16","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.hrthm.2021.06.1172","volume":"18","author":"C Steinberg","year":"2021","unstructured":"Steinberg C, Champagne J, Deyell MW, et al. Prevalence and outcome of early recurrence of atrial tachyarrhythmias in the Cryoballoon vs Irrigated Radiofrequency Catheter Ablation (CIRCA-DOSE) study. Heart Rhythm. 2021;18(9):1463\u201370. https:\/\/doi.org\/10.1016\/j.hrthm.2021.06.1172.","journal-title":"Heart Rhythm"},{"issue":"3","key":"1938_CR17","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.hrthm.2020.11.020","volume":"18","author":"H Calkins","year":"2021","unstructured":"Calkins H, Gache L, Frame D, et al. Predictive value of atrial fibrillation during the postradiofrequency ablation blanking period. Heart Rhythm. 2021;18(3):366\u201373. https:\/\/doi.org\/10.1016\/j.hrthm.2020.11.020.","journal-title":"Heart Rhythm"},{"issue":"3","key":"1938_CR18","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/jce.15337","volume":"33","author":"DA Vrachatis","year":"2022","unstructured":"Vrachatis DA, Papathanasiou KA, Kossyvakis C, et al. Early arrhythmia recurrence after cryoballoon ablation in atrial fibrillation: a systematic review and meta-analysis. J Cardiovasc Electrophysiol. 2022;33(3):527\u201339. https:\/\/doi.org\/10.1111\/jce.15337.","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"5","key":"1938_CR19","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1093\/europace\/euaa041","volume":"22","author":"J Dretzke","year":"2020","unstructured":"Dretzke J, Chuchu N, Agarwal R, et al. Predicting recurrent atrial fibrillation after catheter ablation: a systematic review of prognostic models. Europace. 2020;22(5):748\u201360. https:\/\/doi.org\/10.1093\/europace\/euaa041.","journal-title":"Europace"},{"key":"1938_CR20","doi-asserted-by":"publisher","unstructured":"Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC\/AHA\/ACCP\/HRS Guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines [published correction appears in Circulation. 2024 Jan 2;149(1):e167]. Circulation. 2024;149(1):e1-e156. https:\/\/doi.org\/10.1161\/CIR.0000000000001193.","DOI":"10.1161\/CIR.0000000000001193"}],"container-title":["Journal of Interventional Cardiac Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-024-01938-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10840-024-01938-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-024-01938-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T08:33:39Z","timestamp":1752136419000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10840-024-01938-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["1938"],"URL":"https:\/\/doi.org\/10.1007\/s10840-024-01938-0","relation":{},"ISSN":["1572-8595"],"issn-type":[{"value":"1572-8595","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,8]]},"assertion":[{"value":"16 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"I. My received travel grant from Biosense Webster. S. Bordignon received speaking honoraria from Biosense Webster, Cardiofocus, Boston Scientific, and Medtronic.\u00a0A. Metzner received speaker\u2019s honoraria and travel grants from Medtronic, Biosense Webster, and EPD Solutions\/Philips and a research grant from Farapulse.\u00a0A. Rillig received travel grants and speaker and consultant fees from Biosense Webster, Medtronic, Cardiofocus, Ablamap, and EPD Solutions\/Philips.\u00a0B. Schmidt received speaking honoraria from Abbott, Biosense Webster, Boston Scientific, Cardiofocus, and Medtronic.\u00a0K-R J. Chun received speaking honoraria from Biosense Webster, Boston Scientific, and Medtronic.\u00a0B. Reissmann received speaker\u2019s honoraria and travel grants from Medtronic.\u00a0M.D. Lemoine received a research grant from Farapulse and travel grant from Biosense, and was supported by the Research Promotion Fund of the Faculty of Medicine (Hamburg, \u201cClinician Scientist Program\u201d).\u00a0P. Kirchhof received research support for basic, translational, and clinical research projects from European Union, British Heart Foundation, Leducq Foundation, Medical Research Council (UK), and German Centre for Cardiovascular Research, from several drug and device companies active in atrial fibrillation, and has received honoraria from several such companies in the past, but not in the last 3\u00a0years. PK is listed as an inventor on two patents held by the University of Birmingham (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}